Application of VVYP peptide or salt thereof in preparing medicine for preventing or treating non-alcoholic fatty liver disease

A fatty liver disease, non-alcoholic technique for use in medicine

Inactive Publication Date: 2018-11-06
JIANGXI HERBFINE HI TECH +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no record about the effect of Val-Val-Tyr-Pro peptide on the prevention and treatment of non-alcoholic fatty liver disease in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of VVYP peptide or salt thereof in preparing medicine for preventing or treating non-alcoholic fatty liver disease
  • Application of VVYP peptide or salt thereof in preparing medicine for preventing or treating non-alcoholic fatty liver disease
  • Application of VVYP peptide or salt thereof in preparing medicine for preventing or treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: Protective effect of Val-Val-Tyr-Pro peptide on fatty acid-induced HepG-2 cell injury

[0027] In this example, the protective effect of Val-Val-Tyr-Pro peptide on hepatic steatosis and inflammatory injury in the occurrence and development of NASH was studied through fatty acid induction experiments performed on HepG-2 cells in vitro.

[0028] 1. Experimental materials

[0029] 1.1 Cells: HepG-2 cells, purchased from the US ATCC cell bank.

[0030] 1.2 Experimental reagents: Val-Val-Tyr-Pro peptide acetate samples, oleic acid and palmitic acid (Sigma).

[0031] 1.3 Equipment and reagents: analytical balance, automatic biochemical analyzer.

[0032] 2. Experimental methods and results

[0033] Select the HepG-2 cell seeding plate, plant a 96-well plate, and the number of cells is 10,000 / well (100 μL). The following groups were set up on the plate: 1) blank group; 2) model group (oleic acid and palmitic acid were prepared at a ratio of 1:2, the concentratio...

Embodiment 2

[0041] Example 2: Effect of Val-Val-Tyr-Pro Peptide on the Course of Steatohepatitis in Mice Induced by Methionine Choline Deficiency (MCD) Diet

[0042] In this example, by establishing a non-alcoholic steatohepatitis (NASH) mouse model, the intervention effect of Val-Val-Tyr-Pro peptide on liver steatosis and inflammatory injury in the occurrence and development of NASH was studied.

[0043] 1. Experimental materials

[0044] 1.1 Test animals: C57BL / 6 mice, male, 60, 18-22g

[0045] 1.2 Test drug: Val-Val-Tyr-Pro peptide acetate sample

[0046] 1.3 Equipment and reagents: analytical balance, automatic biochemical analyzer

[0047] 2. Experimental method

[0048] By feeding C57BL / 6 mice with a methionine choline-deficient (MCD) diet for 2 weeks, a non-alcoholic steatohepatitis ((NASH) mouse model was established. Val-Val-Tyr-Pro peptide low (2mg / kg) and high (8mg / kg) dose groups. Collect serum and liver tissue samples from the model group, intervention group and control g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicines, in particular to application of VVYP peptide or salt thereof in preparing medicine for preventing or treating a non-alcoholic fatty liver disease, and the amino acid sequence of the VVYP peptide is Val-Val-Tyr-Pro. The invention further provides a pharmaceutical composition containing therapeutically effective amount of VVYP peptide and the salt thereof and one or multiple excipients, and the composition can be prepared into an oral preparation and contains the peptide with the therapeutically effective amount being 10-50 mg and the salt thereof. The Val-Val-Tyr-Pro peptide is obviously superior to bicyclol in the aspects of protecting liver mitochondria and lowering lipid. A new clinical method is provided for treating and preventing the non-alcoholic fatty liver disease, and the potential medical field of the VVYP peptide is broadened.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to the application of VVYP peptide or its salt in the preparation of drugs for preventing or treating non-alcoholic fatty liver disease. Background technique [0002] Non-alcoholic fatty liver disease is one of the important chronic liver diseases that endanger human health, and its incidence is increasing day by day. The current incidence in the world is about 20%. Non-alcoholic fatty liver disease itself can affect the progression of other chronic liver diseases, and it is mutually causal with the onset of metabolic syndrome. Since its pathogenesis is still unclear, there is a lack of effective control measures. [0003] Val-Val-Tyr-Pro peptide (i.e. VVYP, wherein, Y stands for: L-tyrosine; V stands for: L-valine; P stands for: L-proline) has many patent documents in Japan Report: Val-Val-Tyr-Pro peptide has the effect of inhibiting the concentration of triglyceride ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/07A61P1/16
CPCA61K38/07A61P1/16
Inventor 金一王日康孙勇兵杨世林李惠兰胡林娣
Owner JIANGXI HERBFINE HI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap